Background The PEXIVAS (Plasma exchange and glucocorticoids in severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis) trial showed that a reduced-dose glucocorticoid regimen (redGC) was non-inferior to a standard-dose regimen (standGC) with respect to death or end-stage kidney disease (ESKD) in patients with ANCA-associated vasculitis (AAV). However, the primary endpoint did not include disease progression or relapse, cyclophosphamide was the main induction therapy and rituximab (RTX)-treated patients tended to have a higher risk of death or ESKD with redGC. We aimed to evaluate the real-world use of redGC. Methods We conducted a retrospective, multicentre study comparing PEXIVAS redGC with standGC in patients with AAV. The primary composite outcome was the occurrence of death, ESKD, AAV progression before remission or relapse within the 12 months following induction. Inverse probability of treatment weighting was used to correct for baseline imbalance between groups. Factors associated with the occurrence of the primary outcome were estimated. Results A total of 234 patients were included. The primary composite outcome occurred in 42/126 (33%) patients with redGC versus 20/108 (19%) with standGC. In unweighted multivariable analysis and in weighted analysis, redGC was independently associated with the primary outcome but not with death or ESKD. Among redGC-treated patients, those with serum creatinine&gt;300 µmol/L were more likely to achieve the primary outcome. RTX-treated patients who received redGC were more likely to experience death or ESKD and to achieve the primary outcome. Conclusion In this study of patients with AAV primarily treated with RTX, redGC was associated with an increased risk of the primary outcome consisting of death, ESKD, AAV progression before remission or relapse.

Sophie Nagle

Yann Nguyen

Mary-Jane Guerry

Thomas Quemeneur

Dimitri Titeca-Beauport

Thomas Crépin

Rafik Mesbah

Idris Boudhabhay

Grégory Pugnet

Céline Lebas

Antoine Néel

Alexandre Karras

Eric Hachulla

Juliette Woessner

Vincent Pestre

Raphaël Borie

Stephane Vinzio

Jean-Baptiste Gouin

Sara Melboucy-Belkhir

Roderau Outh

Benjamin Subran

Mathieu Gerfaud-Valentin

Sebastien Humbert

Philippe Kerschen

Yurdagul Uzunhan

Tiphaine Goulenok

Maxime Beydon

Nathalie Costedoat-Chalumeau

Xavier Puechal

Benjamin Terrier

Annals of the Rheumatic Diseases

Real-life use of the PEXIVAS reduced-dose glucocorticoid regimen in granulomatosis with polyangiitis and microscopic polyangiitis

真实世界中PEXIVAS减量糖皮质激素方案在肉芽肿性多血管炎和小血管炎中的应用

Objectives To identify phenotype clusters and their trajectories in psoriatic arthritis (PsA) and examine the association of the clusters with treatment response in a real-world setting. Methods In the multicentre PsA Research Consortium (PARC) study, we applied factor analysis of mixed data to reduce dimensionality and collinearity, followed by hierarchical clustering on principal components. We then evaluated the transition of PsA clusters and their response to new immunomodulatory therapy and tumour necrosis factor inhibitor (TNFi). Results Among 627 patients with PsA, three clusters were identified: mild PsA and psoriasis only (PsO) (Cluster 1, 47.4%), severe PsA and mild PsO (Cluster 2, 34.3%) and severe PsA and severe PsO (Cluster 3, 18.3%). Among 339 patients starting or changing, significant differences in response were observed (mean follow-up of 0.7 years, SD 0.8), with Cluster 3 showing the largest improvements in cDAPSA and PsAID. No differences were found among those starting TNFi (n=218). cDAPSA remission and PsAID patient acceptable symptom state were achieved in 10% and 54%, respectively. Clusters remained stable over time despite treatment changes, though some transitions occurred, notably from Cluster 3 to milder clusters. Conclusion Data-driven clusters with distinct therapy responses identified in this real-world study highlight the extensive heterogeneity in PsA and the central role of psoriasis and musculoskeletal severity in treatment outcomes. Concurrently, these findings underscore the need for better outcome measures, particularly for individuals with lower disease activity.

Paras Karmacharya

Leslie J Crofford

Daniel W Byrne

Alisa Stephens-Shields

M Elaine Husni

Jose U Scher

Ethan Craig

Robert Fitzsimmons

Soumya M Reddy

Marina N Magrey

Jessica A Walsh

Alexis Ogdie

Psoriatic arthritis phenotype clusters and their association with treatment response: a real-world longitudinal cohort study from the psoriatic arthritis research consortium

银屑病关节炎表型簇及其与治疗反应的关联：来自银屑病关节炎研究联盟的真实世界纵向队列研究

Objectives To explore the relapse rate after glucocorticoid (GC) withdrawal with or without hydroxychloroquine (HCQ) maintenance in sustained clinically inactive systemic lupus erythematosus (SLE). Methods The PRESS trial is a multicentre, 33-week, open-label, three-arm, non-inferiority designed, randomised controlled trial. SLE patients with sustained clinically inactive disease who were maintained on low-dose GC plus HCQ therapy were screened and qualified patients were randomly assigned to three groups: drug-free group (both GC and HCQ withdrawal); HCQ group (discontinued GC but maintained HCQ); dual maintenance group (both GC and HCQ continued). The primary endpoint was to compare the proportion of patients experiencing a relapse as defined by the Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index flare index by 33 weeks. Two parallel non-inferiority analyses were performed (drug-free group vs dual maintenance group and HCQ group vs dual maintenance group). Results From 3 November 2016 to 13 August 2021, 333 participants complied with the protocol after randomisation were analysed. The relapse rates in the three groups were 26.1%, 11.2% and 4.7%, respectively. Compared with dual maintenance group, drug-free group failed to achieve non-inferiority significance (relapse rate difference 21.4%; 95% CI 12.3% to 30.5%; P non-inferiority =0.238), whereas HCQ group achieved non-inferiority (relapse rate difference 6.5%; 95% CI −0.5% to 13.5%; P non-inferiority =0.034). HCQ group also exhibited fewer relapses than drug-free group (p=0.006). Adverse events were similar among all three groups. Conclusions GC withdrawal may be feasible in sustained clinically inactive SLE patients. HCQ maintenance can exert a protective role in preventing disease relapse after GC withdrawal. Trial registration number NCT02842814 .

Yunyun Fei

Lidan Zhao

Lijun Wu

Xiaoxia Zuo

Rongli Li

Jiaomei Cheng

Hui Luo

Xue Wu

Li Sun

Jingjing Xu

Yingxuan Zhu

Yang Wang

Zhu Chen

Xiaomei Li

Xiaofei Wang

Xuan Zhang

Evaluation and prediction of relapse risk in stable systemic lupus erythematosus patients after glucocorticoid withdrawal (PRESS): an open-label, multicentre, non-inferiority, randomised controlled study in China

稳定期系统性红斑狼疮患者停用糖皮质激素后复发风险的评估与预测（PRESS）：一项在中国开展的开放标签、多中心、非劣效性、随机对照研究

Kenneth Frank Baker

Julia Spierings

Martin Brom

Timothy Radstake

Emma Smith

Roberta Weiss

Gerd R Burmester

Ann Rheum Dis

Cure as a treatment target in rheumatoid arthritis and systemic sclerosis—achievable aim or mission impossible? FOREUM stimulates new industry-academia collaboration

治愈作为类风湿性关节炎和系统性硬化症的治疗目标——可实现的目标还是不可能的任务？FOREUM 促进新的产学研合作

A EULAR task force was convened to develop points to consider (PtC) for patient education in physical activity and self-management of pain in young people with juvenile-onset rheumatic and musculoskeletal diseases during transitional care.

Javier Courel-Ibáñez

Rafael Prieto-Moreno

Erica Briones-Vozmediano

Patrocinio Ariza-Vega

Saskya Angevare

Jordi Anton

Ilaria Bini

Daniel Clemente

Matilde Correia

Wendy Costello

Diederik De Cock

Andrea Domján

Leticia Leon

Andréa Marques

Kirsten Minden

Ana Filipa Mourão

Aurélie Najm

Seza Ozen

Georgina Pimentel

Zainab Saleem

Tomas Vetrovsky

Nico M Wulffraat

Andrea Zacarias Crovato

Yeliz Prior

Loreto Carmona

Fernando Estévez-López

EULAR points to consider for patient education in physical activity and self-management of pain during transitional care

EULAR关于过渡期护理中患者教育在身体活动和疼痛自我管理方面的考虑要点

To examine the association between study characteristics and the harms reported in randomised controlled trials (RCTs) on biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in patients with inflammatory arthritis (IA).

Johannes Iuel Berg

Sabrina Mai Nielsen

Esben Malm

John P A Ioannidis

Daniel E Furst

Josef S Smolen

Peter C Taylor

Lars Erik Kristensen

Simon Tarp

Torkell Ellingsen

Robin Christensen

Influence of study characteristics on harm estimates from randomised controlled trials in patients with inflammatory arthritis receiving biological or synthetic antirheumatic drugs: a meta-epidemiological study

研究特征对接受生物或合成抗风湿药物的炎性关节炎患者随机对照试验中危害估计的影响：一项元流行病学研究

This work aimed to resolve the conflicting reports on Prevotellaceae abundance in the development of rheumatoid arthritis (RA) and to observe structural, functional and temporal changes in the gut microbiome in RA progressors versus non-progressors.

Christopher M Rooney

Ian B Jeffery

Kulveer Mankia

Mark H Wilcox

Paul Emery

Dynamics of the gut microbiome in individuals at risk of rheumatoid arthritis: a cross-sectional and longitudinal observational study

肠道微生物群在类风湿性关节炎高风险个体中的动态变化：一项横断面和纵向观察性研究

Smoking has been associated with an increased risk of developing rheumatoid arthritis (RA) in individuals carrying shared epitope (SE) HLA-DRB1 alleles. Yet, little is known about the regional and systemic T cell dynamics of smoking and a potential link to T cell infiltration in inflamed synovia. In this study, we, therefore, sought to study T cell features in lung and inflamed joints in smoking versus non-smoking patients.

Koen Venken

Matthias Jarlborg

Frederik Stevenaert

Thomas L A Malfait

Carolien Vlieghe

Yann Abraham

Teddy Manuello

Tine Decruy

Stijn Vanhee

Hans Wils

Pieter J Peeters

Philippe Carron

Filip Van den Bosch

Viggo Van Tendeloo

Bart N Lambrecht

Ruth Wittoek

Peggy Jacques

Dirk Elewaut

Shared lung and joint T cell repertoire in early rheumatoid arthritis driven by cigarette smoking

早期类风湿性关节炎中共享的肺和关节T细胞受体库受吸烟驱动

Objectives Belimumab is a putative disease-modifying agent in systemic lupus erythematosus (SLE), yet the molecular underpinnings of its effects and the ability to predict early clinical response remain unexplored. To address these, we undertook a longitudinal, in-depth blood transcriptome study. Methods RNA-sequencing was performed in the blood of active SLE patients at baseline and following 6 months of belimumab treatment (n=45 paired samples). Clinical response was determined according to the SLE Responder Index (SRI)-4 and Lupus Low Disease Activity State (LLDAS). Weighted correlation network analysis (WGCNA) was used to uncover gene module trait associations. Reversibility of SLE susceptibility and severity gene signatures was assessed. Machine learning was used to build models predictive of response. Results Belimumab induced widespread transcriptome changes with downregulation of pathways related to B cells, type I/II interferon, IL-6/STAT3 and neutrophil activation. These effects were more pronounced among patients with LLDAS+ compared with to SRI-4+/LLDAS– response, with amelioration of the SLE ‘susceptibility’ signature observed in the former group. Unsupervised analysis unveiled gene modules enriched in neutrophil degranulation, type I interferon signalling and cytokine production to correlate positively with response at 6 months. Using neural networks, a set of 50 genes (including CCL4L2, CARD10, MMP1 5 and KLRC2 ) predicted response to belimumab with a cross-validated 84% specificity (test set). Lack of response was linked to perturbations of the cell cycle checkpoints, PI3K/Akt/mammalian target of rapamycin and TGF-beta signalling pathways. Conclusion Belimumab treatment ameliorates multiple innate and adaptive immunity dysregulations of SLE and may reverse the disease signature, consistent with the drug effects on reducing activity and preventing flares. Fingerprints of innate immunity correlate with robust improvement whereas DNA damage response with less responsive disease to BAFF inhibition.

Georgia-Savina Moysidou

Panagiotis Garantziotis

George Sentis

Dimitra Nikoleri

Nikolaos Malissovas

Myrto Nikoloudaki

Eirini-Maria Stergioti

Styliani Polia

Nikolaos Paschalidis

Anastasia Filia

Maria Grigoriou

Dionysis Nikolopoulos

Noemin Kapsala

Spyridon Katechis

Antonis Fanouriakis

George Bertsias

Dimitrios T Boumpas

Molecular basis for the disease-modifying effects of belimumab in systemic lupus erythematosus and molecular predictors of early response: blood transcriptome analysis implicates the innate immunity and DNA damage response pathways

贝利尤单抗在系统性红斑狼疮中的疾病修饰作用及其分子基础和早期反应的分子预测因子：血液转录组分析揭示了先天免疫和DNA损伤反应通路的作用

The EULAR recommendations for the treatment of systemic sclerosis (SSc) were updated in 2017, informed by a systematic literature review (SLR) completed in 2014.

Alain Lescoat

Eugenia Bertoldo

Jelena Čolić

Tania Santiago

Yossra A Suliman

Jenny Emmel

Philip G Conaghan

Yannick Allanore

Francesco del Galdo

Results from the international collaborative systematic literature review informing the 2023 EULAR recommendations for the treatment of systemic sclerosis

国际合作系统文献综述结果为2023年欧洲抗风湿病联盟系统性硬化症治疗建议提供依据

风湿病年鉴 (ARD) 是一份国际同行评审期刊，致力于促进最高标准的科学交流和教育。它涵盖了风湿病学的所有方面，包括肌肉骨骼疾病、关节炎疾病和结缔组织疾病的谱系。 ARD 发表基础、临床和转化科学研究。鼓励简明的科学交流，并以同行评审的国际会议论文集为特色。教育论文包括最先进的评论、“如何”文章和教育案例，重点关注临床实践中面临的问题。该杂志于 1939 年首次出版，拥有权威的全球编辑委员会和不断增长的国际读者群。

The Annals of the Rheumatic Diseases (ARD) is an international peer-reviewed journal dedicated to promoting the highest standards of scientific communication and education. It covers all aspects of rheumatology, including musculoskeletal disorders, arthritic diseases, and connective tissue diseases. ARD publishes basic, clinical, and translational scientific research, encouraging concise scientific communication and featuring peer-reviewed conference proceedings. Educational papers include cutting-edge reviews, 'how-to' articles, and educational cases, focusing on issues faced in clinical practice. Since its first publication in 1939, the journal has maintained a prestigious global editorial board and a growing international readership.

《Annals of the Rheumatic Diseases》（风湿病年鉴，ARD）是一份国际同行评审的学术期刊，旨在促进高标准的科学交流与教育。期刊涵盖风湿病学的各个方面，包括肌肉骨骼疾病、关节炎和结缔组织疾病等。ARD发表基础研究、临床研究和转化科学研究，鼓励简洁明了的科学交流，并定期刊登国际会议的同行评审论文。教育类论文包括前沿评论、实用指南和教育案例，重点关注临床实践中遇到的问题。该杂志自1939年创刊以来，拥有权威的全球编辑委员会和不断扩大的国际读者群。

Journals	Annals of the Rheumatic Diseases
ISSN	0003-4967, 1468-2060
h-index	288
Journal Impact	20.18
Quartiles(Global)	RHEUMATOLOGY(Q1)
Quartiles(China)	医学(1区)医学风湿病学(1区)